Josep Tabernero
YOU?
Author Swipe
View article: Erdafitinib in Patients with <i>FGFR-</i> altered Advanced or Metastatic Cholangiocarcinoma
Erdafitinib in Patients with <i>FGFR-</i> altered Advanced or Metastatic Cholangiocarcinoma Open
Purpose: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations; erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evalu…
View article: Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy Open
Purpose: Prior studies have suggested the biomarker potential of plasma-derived ctDNA in patients with cancer treated with immune checkpoint inhibitors. This study investigated the ability of ctDNA to predict progression-free and overall s…
View article: Developing evidence‐based, cost‐effective <scp>P4</scp> cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Developing evidence‐based, cost‐effective <span>P4</span> cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities Open
The cancer problem is expanding, particularly in low‐ and middle‐income countries (LMICs). Preventive measures can reduce the incidence by 40–50%, and cure rates have increased during the past decades in a number of cancers. However, optim…
View article: Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors Open
Purpose: Cergutuzumab amunaleukin (CA) is an immunocytokine comprising a variant form of interleukin 2 (IL2) [constructed to avoid CD25 binding and regulatory T-cell (Treg) stimulation] fused to a carcinoembryonic antigen (CEA)–targeted an…
View article: Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up Open
ClinicalTrials.gov Identifier: NCT03777657.
View article: Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis Open
Background Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1s, have transformed cancer care by their extended efficacy, even receiving next-line. Event-free survival 2 (EFS2), progression/recurrence-free survival 2 (PRFS2) and…
View article: The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer
The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer Open
The combination of 5-fluorouracil and irinotecan (FOLFIRI) remains a standard-of-care treatment for metastatic colorectal cancer (mCRC) yet benefits only about half of patients. Using patient-derived xenografts, we investigated the biologi…
View article: Supplementary Methods from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Supplementary Methods from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Supplementary Methods
View article: Table 2 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 2 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Contingency table comparing BRAFV600E status between the CTA and F1LCDx
View article: Table S5. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S5. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Summary statistics of estimated log(HR) and ORR difference for the F1LCDx+/CTA+ population (𝜹𝟏) on imputed complete data.
View article: Table S2. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S2. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Plasma sample sizes and sources for LBx testing.
View article: Table S4. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S4. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Summary statistics of PPA and PPV after including imputed data.
View article: Table S1. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S1. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Representativeness of the patient population analyzed.
View article: Figure 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Figure 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Sample processing flow chart. LC, library construction; QC, quality control; SEQ, sequencing. aData from these samples are not included in this study. bPlasma sample was not available for testing with LBx. cMatching plasma comes from clini…
View article: Table 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Demographics and clinical characteristics in the LBx test-evaluable and -unevaluable subsets
View article: Data from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Data from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Purpose:The BRAF inhibitor encorafenib (Enco) plus the anti-EGFR antibody cetuximab (Cetux) improved overall survival, objective response rate, and progression-free survival in previously treated BRAFV600E-mutant metastatic colorectal canc…
View article: Table 4 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 4 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Primary efficacy in the bridging study subpopulations
View article: Table S3. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S3. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Tumor fraction in F1LCDx−/CTA+ and F1LCDx+/CTA− subsets.
View article: Table 3 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table 3 from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Concordance analysis results
View article: Table S6. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer
Table S6. from Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i><sup>V600E</sup> in Colorectal Cancer Open
Estimated efficacy for the F1LCDx+ population in the sensitivity analysis.
View article: Implementation of the precision oncology program in catalonia’s public health system: results, lessons learned, and future prospects
Implementation of the precision oncology program in catalonia’s public health system: results, lessons learned, and future prospects Open
This POP successfully addressed operational, financial, and logistic challenges, ensuring equitable access to molecular testing. This program led to more efficient and personalized clinical management, with growing impact on cancer care an…
View article: Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial
Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial Open
Background: In colorectal cancer (CRC), the liver is the most common site of metastasis, which is the leading cause of CRC-related mortality. Hepatic resection offers long-term survival in some patients with CRC liver metastases (CRLM), bu…
View article: Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i> V600E in Colorectal Cancer
Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i> V600E in Colorectal Cancer Open
Purpose: The BRAF inhibitor encorafenib (Enco) plus the anti-EGFR antibody cetuximab (Cetux) improved overall survival, objective response rate, and progression-free survival in previously treated BRAFV600E-mutant metastatic colorectal can…
View article: Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches
Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches Open
Metastatic colorectal cancer (mCRC) remains a major clinical challenge; however, tumor burden significantly influences treatment outcomes. In this review, we explore the biological and clinical relevance of low tumor burden (LTB) in mCRC. …
View article: Data from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
Data from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study Open
Purpose:Immune checkpoint inhibitors combined with chemotherapy have provided successful results in patients with gastric and gastroesophageal junction (G/GEJ) cancers in the metastatic setting. Similar strategies have been explored in ear…
View article: Figure 2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
Figure 2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study Open
Tissue biomarker analyses and the VIGex score. A, Immune tumor contexture of the basal samples and surgical specimens in patients with MPR (n = 8) and without MPR (n = 25). B, Gene expression profile on surgical specimens, integrated withi…
View article: Supplementary Figure S2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
Supplementary Figure S2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study Open
Supplementary Figure 2: Tertiary lymphoid structures in surgical tumor samples, analysed separately depending on tumor response.